RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

This article was originally published here

RAPT is developing RPT193 initially for the treatment of atopic dermatitis, and subsequently plans to expand clinical development into allergic asthma and other allergic inflammatory diseases. “The onset

The post RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply